Highlights
- Surrozen, a Wnt pathway biotechnology company, entered into an Underwriting agreement for a common stock offering.
- Third quarter 2026 net loss was $129,724 thousand, or $11.02 per share, compared with $71,643 thousand, or $8.36.
- Boehringer Ingelheim filed an ICC arbitration request in October 2026 seeking a 50% reduction of Royalty and milestone payment obligations.
- Cash and cash equivalents were $100.4 million at September 30, 2026, and the company anticipates a cash runway into 2029.
Surrozen, Inc. (NASDAQ:SRZN) shares were trading at USD 29.36 on November 17, 2026, down 9.17%, with a relative Volume at time of 2.20. The biotechnology company received FDA clearance of its IND application for SZN-8141 in October 2026, has dosed its first DUET patient, filed its third quarter report on November 9 and entered into an underwriting agreement for a common stock offering.
Surrozen is a Delaware corporation with principal executive offices in South San Francisco, California. It develops multi-specific, antibody-based therapeutics designed to modulate the Wnt pathway, with a current strategic focus on ophthalmology. Its programs include SZN-8141 for diabetic macular edema and neovascular age-related macular degeneration, SZN-8143 for retinal diseases, and SZN-413, which is licensed to Boehringer Ingelheim. It has generated Revenue only from licensing and research collaborations. As of November 5, 2026, 19,061,662 shares of common stock were outstanding.
Underwriting Agreement and Financing
Surrozen entered into an underwriting agreement for a common stock offering. The company also reported other Equity Financing in October 2026. It closed the second Tranche of its 2025 private placement, issuing 5.7 million shares of common stock, pre-funded warrants to purchase up to 2.5 million shares and Series E common stock warrants to purchase up to 4.1 million shares, for aggregate gross proceeds of approximately $95.1 million. It sold a total of 1.2 million shares under its 2026 at-the-market program for net proceeds of $29.8 million, and Warrant exercises of 0.1 million shares produced gross proceeds of $1.1 million.
The company states that any future financing through sales of equity securities will cause its stockholders to experience dilution.
Third Quarter 2026 Results
For the quarter ended September 30, 2026, Surrozen reported no revenue, compared with total revenue of $983 thousand a year earlier. Research and Development expenses were $10,837 thousand, compared with $7,774 thousand, and general and administrative expenses were $6,805 thousand, compared with $4,094 thousand. Loss from operations was $17,642 thousand, compared with $10,885 thousand.
The net loss was $129,724 thousand, or $11.02 per share, compared with $71,643 thousand, or $8.36. The net loss included a noncash loss of $113.0 million on changes in Fair Value of tranche Liability and warrant liabilities. For the nine months, the net loss was $207,052 thousand, compared with $58,867 thousand, and revenue was $10,000 thousand, compared with $2,949 thousand, reflecting milestones under the Boehringer Ingelheim agreement.
Boehringer Ingelheim Dispute, Cash and Balance Sheet
In June 2026, Boehringer Ingelheim achieved a development milestone that triggered a $10.0 million payment. The company recognized $5.0 million as revenue and holds the other $5.0 million as a liability. Boehringer Ingelheim advised that it believes it has grounds to seek restitution of $5.0 million. In October 2026, it filed a request for arbitration with the International Chamber of Commerce asserting a material breach and seeking a 50% reduction of royalty and milestone payment obligations. Surrozen submitted its response in November 2026 denying the allegations in full and has recorded no additional liability.
At September 30, 2026, cash and cash equivalents were $100.4 million, total Assets were $109,035 thousand, total liabilities were $444,657 thousand and the accumulated Deficit was $734.3 million. Net cash used in Operating Activities for the nine months was $24,738 thousand.
Outlook and Plans
The company expects topline data from the DUET Phase 1b in the second half of 2027 and from the Phase 2a in 2028, and plans to expand Part 2 from approximately 60 to 150 patients. It anticipates a cash runway into 2029, including completion of the DUET Phase 1b/2a study and initial Phase 1b development of SZN-8143. It believes its existing cash and October 2026 proceeds are sufficient to fund operations for at least the next 12 months from the filing date.
The company expects to continue to incur losses and says its ability to continue as a Going Concern in the long-term depends on securing financing and achieving profitable operations.






Please wait processing your request...